Takeda Boosts Global Vaccine Business with LigoCyte Pharmaceuticals Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 10 (Table of Contents)
Published: 29 Oct-2012
DOI: 10.3833/pdr.v2012.i10.1826 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Takeda Pharmaceutical has agreed to acquire the US-based vaccine developer LigoCyte Pharmaceuticals and its pipeline of virus-like particle (VLP)-based vaccines for gastrointestinal and respiratory indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS